<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566679</url>
  </required_header>
  <id_info>
    <org_study_id>BUZIR2020</org_study_id>
    <nct_id>NCT04566679</nct_id>
  </id_info>
  <brief_title>Butyrate in Children With IBS: Double Blind Placebo Controlled Randomized Clinical Trial</brief_title>
  <acronym>BUZIR</acronym>
  <official_title>Butyrate in Children With IBS: Double Blind Placebo Controlled Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bari</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will perform a randomized, double-blind, placebo-controlled trial to establish whether&#xD;
      calcium butyrate relieves symptoms in children with irritable bowel syndrome (IBS). The&#xD;
      direct effects of butyrate on inflammation and GI symptoms will be studied in children with&#xD;
      IBS. The design used to study the effects of calcium butyrate will be a double blind&#xD;
      randomized placebo-controlled parallel design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study plan 2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10)&#xD;
      and a 4- week follow-up phase (weeks 11-14).&#xD;
&#xD;
      Randomization Enrolled children will be randomly assigned, with the use of a&#xD;
      computer-generated randomization list to receive either oral butyrate (500 mg) or oral&#xD;
      placebo once (twice) per day. Placebo and butyrate had the same shape, the placebo's taste,&#xD;
      dimension, indication, and appearance.&#xD;
&#xD;
      Data Collection A diary will be given to the parents; on a daily basis, patients will monitor&#xD;
      and record the frequency/severity of symptoms and school absence on the diary. To assess the&#xD;
      severity of pain, a combination of the self-reported visual analog scale (VAS) and the Faces&#xD;
      Pain Scale (FPS) will be used. The 0- to 10-mm VAS scale (0, no pain; 10, worst possible&#xD;
      pain) include a horizontal color gradient (green to red) plus a rating. Daily, when asked to&#xD;
      evaluate pain, the child would point to a level and trace a line. Assessment will be done&#xD;
      coupling the VAS with the FPS, which consists of 6 faces that range from a relaxed face to a&#xD;
      face that shows intense pain (von Baeyer CL). GSRS Participants will be asked to fill out the&#xD;
      GSRS every 2 weeks during running in, treatment, and follow up (Svedlund).&#xD;
&#xD;
      Compliance To ensure compliance, the investigator will contact the families every 4 weeks to&#xD;
      monitor the process of the study.&#xD;
&#xD;
      Adherence will be assessed by counting the number of capsules returned; children who will&#xD;
      miss taking more than 20% of the medication will be considered noncompliant.&#xD;
&#xD;
      Fecal Analysis Fecal samples for microbiological analysis will be collected before treatment&#xD;
      and at week 10 (end of treatment) and week 14 (4 weeks after discontinuation). Urinary NMR&#xD;
      Analysis Urinary samples for NMR analysis will be collected before treatment and at week 10&#xD;
      (end of treatment) and week 14 (4 weeks after discontinuation). This method is described by&#xD;
      Lussu et al .&#xD;
&#xD;
      Fecal lactoferrin and calprotectin Fecal calprotectin will be measured using a commercial&#xD;
      Fecal Calprotectin Immunoassay kit (Genova Diagnostics, Asheville, NC), respectively,&#xD;
      following the manufacturers&amp;#39; instructions.&#xD;
&#xD;
      Sample size calculation To demonstrate an efficacy of butyrate, considering a placebo effect&#xD;
      of 20% and a difference in response of at least 35%, keeping a power of the study of 80% and&#xD;
      a p of 0,05 we need 23 patients for group that, considering a drop out of 10%, will became 25&#xD;
      per group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>butyrate on GI symptoms</measure>
    <time_frame>daily for 14 weeks</time_frame>
    <description>To assess the severity of pain, a combination of the self-reported visual analog scale (VAS) and the Faces Pain Scale (FPS) will be used. The 0- to 10-mm VAS scale (0, no pain; 10, worst possible pain) include a horizontal color gradient (green to red) plus a rating.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>butyrate on GI symptoms</measure>
    <time_frame>every two weeks for 14 weeks</time_frame>
    <description>Gastrointestinal Symptom Rating Scale (GSRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>butyrate on inflammation</measure>
    <time_frame>14 weeks</time_frame>
    <description>fecal calprotectin and lactoferrin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Irritable Bowel Syndrome (IBS)</condition>
  <condition>Children, Only</condition>
  <arm_group>
    <arm_group_label>Butyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral butyrate (500mg) once or twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo once or twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dibuzin</intervention_name>
    <description>2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)</description>
    <arm_group_label>Butyrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of IBS according to the Rome IV diagnostic criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any chronic diseases&#xD;
&#xD;
          -  Treatment with antibiotics/prebiotics/probiotic/postbiotic in the previous two months&#xD;
&#xD;
          -  Diagnosis of another functional GI disease&#xD;
&#xD;
          -  Growth failure or others alarming signs of organic conditions&#xD;
&#xD;
          -  Previous abdominal surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pediatric Department &quot;B Trambusti&quot; Ospedale Giovanni XXIII Via Amendola 270</name>
      <address>
        <city>Bari</city>
        <state>Ba</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Cristofori</last_name>
      <phone>0805592847</phone>
      <email>fernandacristofori@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ruggiero Francavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernanda Cristofori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica</name>
      <address>
        <city>Bari</city>
        <state>Puglia</state>
        <zip>70125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruggiero Francavilla</last_name>
      <phone>080-5592360</phone>
      <email>rfrancavilla@libero.it</email>
    </contact>
    <investigator>
      <last_name>Ruggiero Francavilla, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Gibson P, Rosella O. Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease. Gut. 1995 Oct;37(4):536-43.</citation>
    <PMID>7489942</PMID>
  </results_reference>
  <results_reference>
    <citation>Ogawa H, Rafiee P, Fisher PJ, Johnson NA, Otterson MF, Binion DG. Butyrate modulates gene and protein expression in human intestinal endothelial cells. Biochem Biophys Res Commun. 2003 Sep 26;309(3):512-9.</citation>
    <PMID>12963019</PMID>
  </results_reference>
  <results_reference>
    <citation>Pozuelo M, Panda S, Santiago A, Mendez S, Accarino A, Santos J, Guarner F, Azpiroz F, Manichanh C. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep. 2015 Aug 4;5:12693. doi: 10.1038/srep12693.</citation>
    <PMID>26239401</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhu L, Ma Y, Ye S, Shu Z. Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis. Evid Based Complement Alternat Med. 2018 May 27;2018:2890465. doi: 10.1155/2018/2890465. eCollection 2018. Review.</citation>
    <PMID>29977312</PMID>
  </results_reference>
  <results_reference>
    <citation>Banasiewicz T, Krokowicz Ł, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, Marciniak R, Krokowicz P, Walkowiak J, Drews M. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013 Feb;15(2):204-9. doi: 10.1111/j.1463-1318.2012.03152.x.</citation>
    <PMID>22738315</PMID>
  </results_reference>
  <results_reference>
    <citation>von Baeyer CL. Children's self-reports of pain intensity: scale selection, limitations and interpretation. Pain Res Manag. 2006 Autumn;11(3):157-62. Review.</citation>
    <PMID>16960632</PMID>
  </results_reference>
  <results_reference>
    <citation>Svedlund J, Sjödin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988 Feb;33(2):129-34.</citation>
    <PMID>3123181</PMID>
  </results_reference>
  <results_reference>
    <citation>Lussu M, Noto A, Masili A, Rinaldi AC, Dessì A, De Angelis M, De Giacomo A, Fanos V, Atzori L, Francavilla R. The urinary (1) H-NMR metabolomics profile of an italian autistic children population and their unaffected siblings. Autism Res. 2017 Jun;10(6):1058-1066. doi: 10.1002/aur.1748. Epub 2017 Mar 11.</citation>
    <PMID>28296209</PMID>
  </results_reference>
  <results_reference>
    <citation>De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serrazzanetti DI, Cristofori F, Guerzoni ME, Gobbetti M, Francavilla R. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One. 2013 Oct 9;8(10):e76993. doi: 10.1371/journal.pone.0076993. eCollection 2013.</citation>
    <PMID>24130822</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bari</investigator_affiliation>
    <investigator_full_name>Ruggiero Francavilla</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome (IBS)</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

